Cardiotoxicity of epirubicin and doxorubicin: Assessment by endomyocardial biopsy

F. M. Torti, M. M. Bristow, B. L. Lum, S. K. Carter, A. E. Howes, D. A. Aston, B. W. Brown, J. F. Hannigan, Frederick J Meyers, E. P. Mitchell

Research output: Contribution to journalArticlepeer-review

165 Scopus citations


Forty-two evaluable endomyocardial biopsies were obtained from 29 patients treated with epirubicin, the 4'-epimer of doxorubicin in cumulative doses ranging from 147 mg/m2 to 888 mg/m2. In this study of the Northern California Oncology Group, myofibrillar loss and sarcoplasmic vacuolization were identified and shown to be identical to those previously described for doxorubicin. However, when these biopsies were compared to 119 biopsies obtained from 98 patients treated with doxorubicin, milligram for milligram, epirubicin caused less endomyocardial injury than doxorubicin (P = 0.0013). Age, sex, type of primary malignancy, prior cardiac disease, and hypertension did not influence the degree of histologically demonstrated anthracycline injury induced by epirubicin.

Original languageEnglish (US)
Pages (from-to)3722-3727
Number of pages6
JournalCancer Research
Issue number7
StatePublished - 1986

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Cardiotoxicity of epirubicin and doxorubicin: Assessment by endomyocardial biopsy'. Together they form a unique fingerprint.

Cite this